73/120
3.0 / 5 stars
All 120 Win/Lose results shown below
ZTS Roast Me summary
Zoetis Inc. (ZTS). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 0 wins, 12 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseZTS / S&P -38.95% / 15.20% |
LoseZTS / S&P 1.49% / 15.00% |
LoseZTS / S&P 5.38% / 50.40% |
| 2026-Q10/3 |
LoseZTS / S&P -5.65% / -4.33% |
LoseZTS / S&P 2.80% / 11.30% |
LoseZTS / S&P 10.00% / 27.70% |
| 2025-Q40/3 |
LoseZTS / S&P -13.71% / 2.65% |
LoseZTS / S&P 2.28% / 9.00% |
LoseZTS / S&P 10.05% / 13.40% |
| 2025-Q30/3 |
LoseZTS / S&P -5.86% / 8.12% |
LoseZTS / S&P 2.59% / 4.61% |
LoseZTS / S&P 10.71% / 13.45% |
| 2025-Q22/3 |
LoseZTS / S&P -4.96% / 10.94% |
WinZTS / S&P 5.18% / 4.83% |
WinZTS / S&P 12.72% / 10.63% |
| 2025-Q12/3 |
WinZTS / S&P 1.36% / -4.27% |
WinZTS / S&P 6.07% / 4.98% |
LoseZTS / S&P 5.97% / 10.57% |
| 2024-Q42/3 |
LoseZTS / S&P -16.41% / 2.41% |
WinZTS / S&P 8.33% / 5.25% |
WinZTS / S&P 7.89% / 6.15% |
| 2024-Q33/3 |
WinZTS / S&P 12.97% / 5.89% |
WinZTS / S&P 9.33% / 5.89% |
WinZTS / S&P 8.35% / 6.11% |
| 2024-Q22/3 |
LoseZTS / S&P 2.74% / 4.28% |
WinZTS / S&P 8.43% / 5.38% |
WinZTS / S&P 7.58% / 5.12% |
| 2024-Q12/3 |
LoseZTS / S&P -14.07% / 10.56% |
WinZTS / S&P 7.91% / 5.71% |
WinZTS / S&P 17.42% / 5.59% |
| 2023-Q42/3 |
WinZTS / S&P 13.72% / 11.69% |
LoseZTS / S&P 5.74% / 6.81% |
WinZTS / S&P 12.92% / 7.78% |
| 2023-Q32/3 |
WinZTS / S&P 1.25% / -3.27% |
LoseZTS / S&P 4.55% / 7.52% |
WinZTS / S&P 12.10% / -5.03% |
| 2023-Q21/3 |
LoseZTS / S&P 3.69% / 8.74% |
LoseZTS / S&P 2.84% / 9.50% |
WinZTS / S&P 7.71% / -8.57% |
| 2023-Q12/3 |
WinZTS / S&P 13.84% / 7.50% |
LoseZTS / S&P 2.57% / 10.77% |
WinZTS / S&P 1.38% / -15.69% |
| 2022-Q41/3 |
LoseZTS / S&P -0.96% / 7.56% |
LoseZTS / S&P 3.91% / 11.88% |
WinZTS / S&P 5.15% / -17.99% |
| 2022-Q31/3 |
LoseZTS / S&P -13.57% / -4.88% |
LoseZTS / S&P 5.13% / 13.47% |
WinZTS / S&P 5.54% / -1.41% |
| 2022-Q21/3 |
WinZTS / S&P -8.70% / -16.10% |
LoseZTS / S&P 7.87% / 13.71% |
LoseZTS / S&P 10.53% / 11.04% |
| 2022-Q10/3 |
LoseZTS / S&P -22.59% / -4.60% |
LoseZTS / S&P 12.54% / 15.97% |
LoseZTS / S&P 17.52% / 42.23% |
| 2021-Q42/3 |
WinZTS / S&P 25.85% / 11.03% |
WinZTS / S&P 16.49% / 15.00% |
LoseZTS / S&P 24.85% / 96.40% |
| 2021-Q32/3 |
WinZTS / S&P 4.31% / 0.58% |
WinZTS / S&P 16.42% / 10.77% |
LoseZTS / S&P 19.60% / 69.42% |
| 2021-Q22/3 |
WinZTS / S&P 18.52% / 8.55% |
WinZTS / S&P 16.91% / 6.58% |
LoseZTS / S&P 18.40% / 51.81% |
| 2021-Q12/3 |
LoseZTS / S&P -4.70% / 6.17% |
WinZTS / S&P 10.62% / -1.06% |
WinZTS / S&P 10.75% / 7.39% |
| 2020-Q42/3 |
LoseZTS / S&P 0.20% / 12.15% |
WinZTS / S&P 6.63% / -3.72% |
WinZTS / S&P 9.97% / -33.42% |
| 2020-Q33/3 |
WinZTS / S&P 20.84% / 8.93% |
WinZTS / S&P 6.37% / -2.04% |
WinZTS / S&P 14.52% / -27.10% |
| 2020-Q22/3 |
LoseZTS / S&P 16.63% / 20.54% |
WinZTS / S&P 4.86% / -0.46% |
WinZTS / S&P 18.66% / -27.11% |
| 2020-Q13/3 |
WinZTS / S&P -10.95% / -19.60% |
WinZTS / S&P 7.19% / 3.47% |
WinZTS / S&P 17.13% / -14.75% |
| 2019-Q42/3 |
LoseZTS / S&P 6.36% / 9.07% |
WinZTS / S&P 7.47% / 5.36% |
WinZTS / S&P 6.14% / 2.99% |
| 2019-Q33/3 |
WinZTS / S&P 9.94% / 1.70% |
WinZTS / S&P 7.50% / 5.02% |
WinZTS / S&P 27.31% / 0.21% |
| 2019-Q23/3 |
WinZTS / S&P 12.92% / 4.30% |
WinZTS / S&P 8.20% / 6.64% |
WinZTS / S&P 24.56% / 8.65% |
| 2019-Q13/3 |
WinZTS / S&P 17.92% / 13.65% |
WinZTS / S&P 8.67% / 8.12% |
WinZTS / S&P 43.72% / 14.29% |
| 2018-Q43/3 |
WinZTS / S&P -6.45% / -13.52% |
WinZTS / S&P 9.76% / 9.05% |
WinZTS / S&P 67.43% / 18.23% |
| 2018-Q32/3 |
LoseZTS / S&P 7.64% / 7.71% |
WinZTS / S&P 11.65% / 10.21% |
WinZTS / S&P 25.26% / 19.06% |
| 2018-Q22/3 |
LoseZTS / S&P 2.16% / 3.43% |
WinZTS / S&P 11.36% / 9.03% |
WinZTS / S&P 28.81% / 14.46% |
| 2018-Q13/3 |
WinZTS / S&P 16.11% / -0.76% |
WinZTS / S&P 9.78% / 7.68% |
WinZTS / S&P 15.70% / 12.46% |
| 2017-Q42/3 |
WinZTS / S&P 13.16% / 6.64% |
WinZTS / S&P 8.57% / 7.03% |
LoseZTS / S&P 6.06% / 13.82% |
| 2017-Q31/3 |
LoseZTS / S&P 2.21% / 4.48% |
LoseZTS / S&P 4.89% / 5.68% |
WinZTS / S&P 36.69% / 17.57% |
| 2017-Q22/3 |
WinZTS / S&P 17.31% / 3.09% |
LoseZTS / S&P 3.29% / 4.83% |
WinZTS / S&P 37.21% / 17.74% |
| 2017-Q11/3 |
LoseZTS / S&P -0.10% / 6.07% |
LoseZTS / S&P 2.74% / 3.67% |
WinZTS / S&P 123.38% / 13.32% |
| 2016-Q42/3 |
LoseZTS / S&P 3.13% / 3.82% |
WinZTS / S&P 2.58% / 2.09% |
WinZTS / S&P 142.65% / 7.05% |
| 2016-Q33/3 |
WinZTS / S&P 9.59% / 3.85% |
WinZTS / S&P 1.54% / 0.20% |
WinZTS / S&P 56.18% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | ZTS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -49.62% | 20.78% |
| Annualized return | -49.62% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | ZTS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -60.39% | 83.14% |
| Annualized return | -16.91% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | ZTS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 65.11% | 319.30% |
| Annualized return | 5.14% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |